Myeloid Toxicity in Breast Cancer Patients Receiving Adjuvant Chemotherapy: What Is the Appropriate Use of Filgrastim?
G. Ferretti(Istituti di Ricovero e Cura a Carattere Scientifico), Paola Papaldo(Cancer Institute (WIA)), Mauro Antimi(Catholic University of America), Paolo Marolla(Catholic University of America), Diana Giannarelli(Agostino Gemelli University Polyclinic), Enrico Cortesi(Sapienza University of Rome), E. Terzoli(Catholic University of America), Massimo Lopez(Catholic University of America), Francesco Cognetti(Apple (Israel))
Cited by 2
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k